• Users Online: 102
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others


Community-acquired pneumonia: Changing paradigms about mortality

Torres Antoni

Year : 2014| Volume: 1| Issue : 1 | Page no: 1-3

   This article has been cited by
1 Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug
Samareh Azeredo da Silveira,Andrew F. Shorr
Antibiotics. 2020; 9(2): 94
[Pubmed]  [Google Scholar]
2 CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial
Pierre-François Laterre,Gwenhael Colin,Pierre-François Dequin,Thierry Dugernier,Thierry Boulain,Samareh Azeredo da Silveira,Frédéric Lajaunias,Antonio Perez,Bruno François
The Lancet Infectious Diseases. 2019;
[Pubmed]  [Google Scholar]
3 Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain
Antoni Torres,Matteo Bassetti,Tobias Welte,Simone Rivolo,Edit Remak,Carmen Peral,Claudie Charbonneau,Jennifer Hammond,Wajeeha Ansari,Santiago Grau
Journal of Medical Economics. 2019; : 1
[Pubmed]  [Google Scholar]
4 CAL02 Liposomes and Other Antitoxins
Samareh Azeredo da Silveira,Antonio Perez
Clinical Pulmonary Medicine. 2018; 25(3): 84
[Pubmed]  [Google Scholar]
5 Improving the fate of severely infected patients: the promise of anti-toxin treatments and superiority trials
Samareh Azeredo da Silveira,Antonio Perez
Expert Review of Anti-infective Therapy. 2017; 15(11): 973
[Pubmed]  [Google Scholar]


Read this article